Typhoid Conjugate Vaccine (TCV)

A conjugate vaccine offering superior and longer-lasting protection against Salmonella typhi compared to older polysaccharide vaccines. India introduced TCV in its UIP in 2021.

The Typhoid Conjugate Vaccine (TCV) is recommended for 9 months – 15 years (single dose); adults as needed. It falls under the Childhood vaccine category. Consult your doctor to confirm if this vaccine is right for you based on your health history and existing immunity.

The Typhoid Conjugate Vaccine (TCV) has an efficacy of 81–87%. This means it provides significant protection against Typhoid Fever. Efficacy may vary based on age, health status, and the specific strain encountered.

Common side effects include: Mild pain and swelling at injection site; low-grade fever; headache. These are typically mild and resolve within 1–3 days. Serious allergic reactions are rare — if you experience difficulty breathing, hives, or rapid heartbeat after vaccination, seek emergency care immediately.

The Typhoid Conjugate Vaccine (TCV) should be avoided by: Severe allergy to a previous dose; acute moderate-to-severe illness. Always inform your healthcare provider of your full medical history before vaccination.

The Typhoid Conjugate Vaccine (TCV) typically costs ₹400 – ₹1,200 in India. Government health centres may offer it free or at subsidised prices for eligible age groups. Private hospitals and clinics may charge differently. Additional fees may apply for administration.